阿托伐他汀对颈动脉狭窄并支架置入术后患者临床预后及炎症因子的影响

Influence of Atorvastatin on Clinical Prognosis and Inflammatory Factors of Patients with Carotid Stenosis Undergoing Stent Implantation

目的:研究阿托伐他汀对颈动脉狭窄并支架置入术后患者临床预后及炎症因子的影响。方法:选取2013年1月到2014年1月我院收治的接受支架置入术的颈动脉狭窄患者90例,按照随机数字表法将患者分为研究组和对照组,每组45例,对照组给予常规治疗,研究组在对照组的基础上给予阿托伐他汀治疗,连续治疗1年,比较两组支架内再狭窄率及不良反应发生率,分析治疗前和治疗后两组超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平。结果:研究组1年内支架再狭窄率显著低于对照组,两组比较差异具有统计学意义(P<0.05);治疗后两组hs-CRP和IL-6水平均显著低于治疗前,且研究组显著低于对照组,比较差异具有统计学意义(P<0.05);两组不良反应比较无统计学意义(P>0.05)。结论:阿托伐他汀治疗颈动脉狭窄并支架置入术患者,能显著降低支架内再狭窄率及炎症因子水平。

Objective： To study the influence of atorvastatin on the clinical prognosis and inflammatory factors of patients with carotid stenosis undergoing stent implantation. Methods： A total of 90 patients with carotid stenosis, who underwent stent implantation in First People＇s Hospital, Jining from January 2013 to January 2014, were randomly divided into study group（n=45） and control group（n=45）. The control group was treated with routine therapy, while the study group was added atorvastatin on the basis of control group＇s therapy, with continuous treatment for 1 years. The restenosis rate and incidence of adverse reactions were compared between the two groups; the high sensitivity-C reactive protein（hs-CRP）, interleukin-6（IL-6） levels in the two groups before and after treatment were analyzed. Results： The restenosis rate within 1 years of study group was significantly lower than that in control group, the difference was statistically significant（P〈0.05）. Compared with before treatment, hs-CRP and IL-6 levels in two groups after treatment significantly decreased, moreover, the study group was significantly lower than the control group,the differences were statistically significant（P〈0.05）.There was no statistical significance in the incidence of adverse reactions between the two groups（P〉0.05）. Conclusion： Atorvastatin can significantly cut down the restenosis rate and inflammatory factors levels in the treatment of patients with carotid stenosis undergoing stent implantation.